Swiss Life Asset Management Ltd Has $13.64 Million Stock Position in HCA Healthcare, Inc. $HCA

Swiss Life Asset Management Ltd cut its stake in HCA Healthcare, Inc. (NYSE:HCA) by 12.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,998 shares of the company’s stock after selling 4,701 shares during the period. Swiss Life Asset Management Ltd’s holdings in HCA Healthcare were worth $13,638,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of HCA. Palisade Asset Management LLC bought a new stake in shares of HCA Healthcare in the 3rd quarter worth about $26,000. Harbor Capital Advisors Inc. boosted its position in HCA Healthcare by 82.9% in the third quarter. Harbor Capital Advisors Inc. now owns 75 shares of the company’s stock valued at $32,000 after buying an additional 34 shares in the last quarter. JPL Wealth Management LLC acquired a new stake in shares of HCA Healthcare during the third quarter worth approximately $33,000. Twin Peaks Wealth Advisors LLC acquired a new position in shares of HCA Healthcare in the 2nd quarter worth approximately $40,000. Finally, Compound Global Advisors LLC acquired a new stake in HCA Healthcare during the 3rd quarter valued at $44,000. 62.73% of the stock is currently owned by institutional investors and hedge funds.

Key HCA Healthcare News

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: Jim Cramer publicly recommended buying HCA, calling it a buy in “big clumps,” which can drive retail interest and short‑term inflows. Jim Cramer on HCA Healthcare
• Positive Sentiment: HCA hospitals received regional/national recognition (Ocala hospitals praised for patient safety; HCA Florida North Florida Hospital named to America’s 250 Best Hospitals), which supports brand, referrals and patient volumes. Ocala hospitals honored for excellence in patient safety
• Positive Sentiment: HCA Florida North Florida Hospital included among America’s 250 Best Hospitals, reinforcing quality credentials that can protect pricing and payer relationships. HCA Florida North Florida Hospital among America’s 250 Best Hospitals
• Positive Sentiment: Virginia regulators approved new hospitals/expansions that include HCA projects, supporting medium‑term revenue growth and market share in that region. State approves three Chesterfield hospital projects
• Neutral Sentiment: Human-interest coverage (a North Carolina NICU St. Patrick’s Day feature) highlights community care but is unlikely to move the stock materially. North Carolina NICU Celebrates St. Patrick’s Day
• Negative Sentiment: HCA’s board urged shareholders to reject a proposal for fuller reporting on the aftermath of the 2019 Mission sale — a governance/oversight flashpoint that can raise investor concern and activist interest. HCA board urges shareholders to reject proposal
• Negative Sentiment: An HCA hospital CEO is leaving for Beth Israel Lahey Health — an executive departure that may be seen as local leadership turnover and could modestly concern investors about continuity in affected markets. HCA hospital CEO heads to Beth Israel Lahey Health

Insider Activity

In related news, EVP Michael S. Cuffe sold 1,500 shares of HCA Healthcare stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $498.09, for a total transaction of $747,135.00. Following the transaction, the executive vice president owned 30,003 shares of the company’s stock, valued at $14,944,194.27. This trade represents a 4.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Christopher F. Wyatt sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $505.00, for a total transaction of $2,020,000.00. Following the completion of the sale, the senior vice president directly owned 44,379 shares of the company’s stock, valued at $22,411,395. The trade was a 8.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 15,214 shares of company stock valued at $7,797,595. Insiders own 1.30% of the company’s stock.

HCA Healthcare Price Performance

HCA opened at $493.61 on Friday. HCA Healthcare, Inc. has a fifty-two week low of $314.43 and a fifty-two week high of $556.52. The company has a market cap of $110.36 billion, a price-to-earnings ratio of 17.39, a price-to-earnings-growth ratio of 1.53 and a beta of 1.34. The firm has a 50 day simple moving average of $510.01 and a 200 day simple moving average of $473.08.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Tuesday, January 27th. The company reported $8.01 EPS for the quarter, beating the consensus estimate of $7.37 by $0.64. HCA Healthcare had a net margin of 8.97% and a negative return on equity of 409.11%. The company had revenue of $19.51 billion during the quarter, compared to analysts’ expectations of $19.67 billion. During the same quarter in the previous year, the company posted $6.22 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 17th will be issued a dividend of $0.78 per share. This represents a $3.12 dividend on an annualized basis and a yield of 0.6%. This is an increase from HCA Healthcare’s previous quarterly dividend of $0.72. The ex-dividend date is Tuesday, March 17th. HCA Healthcare’s dividend payout ratio (DPR) is 10.99%.

Analyst Ratings Changes

A number of analysts have recently weighed in on HCA shares. Leerink Partners raised their target price on HCA Healthcare from $507.00 to $573.00 and gave the company an “outperform” rating in a research note on Wednesday, January 28th. Wells Fargo & Company increased their price objective on shares of HCA Healthcare from $452.00 to $481.00 and gave the stock an “equal weight” rating in a report on Friday, January 30th. Argus upped their target price on shares of HCA Healthcare from $530.00 to $560.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Barclays raised their price target on shares of HCA Healthcare from $494.00 to $551.00 and gave the company an “overweight” rating in a report on Wednesday, January 28th. Finally, Zacks Research lowered HCA Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 27th. Sixteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $537.73.

HCA Healthcare Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.